Schoenfeld, A., Arbour, K., Rizvi, H., Iqbal, A., Gadgeel, S., Girshman, J., . . . Hellmann, M. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol.
Styl ChicagoSchoenfeld, A.J., et al. "Severe Immune-related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib." Ann Oncol 2019.
Citace podle MLASchoenfeld, A.J., et al. "Severe Immune-related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib." Ann Oncol 2019.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..